Research programme: CNS disease therapeutics - Evotec/Roche
Latest Information Update: 06 Jan 2010
At a glance
- Originator Evotec AG; Roche
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 06 Jan 2010 This programme is in active development